New York, N.Y. - Mar 17, 2009 - InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR), today announced that RESPeRATE , the world's first FDA-cleared, over-the-counter blood pressure treatment device, is now being sold in 100 Boots Pharmacy stores throughout the UK. InterCure is supporting the launch with a variety of advertisements and in-store promotions with Boots.

The new distribution of RESPeRATE at Boots continues InterCure's retail momentum. InterCure entered the UK pharmacy market in 2008, achieving broad distribution at 1,400 Lloyds Pharmacy stores and continues to expand its footprint in independent pharmacies through two wholesalers, Mashco and Colorama. In the US, InterCure announced last week that RESPeRATE is now available at more than 800 West Coast Rite Aid locations.

"Boots is a trusted pharmacy in the UK, with a reputation of being a reliable source of high-quality care," said Erez Gavish, president and CEO of InterCure. "For InterCure, this agreement marks an important step in the expansion of RESPeRATE into the retail market, and we are steadfast in our mission to continue placing RESPeRATE onto pharmacy shelves and into the homes of anyone seeking a proven, personal therapeutic device."

RESPeRATE is FDA-cleared for over-the-counter sale and is the only medical device on the market clinically-proven to lower blood pressure through paced breathing therapy. The device uses the body's natural tendency to follow external rhythms, interactively guiding the user to effortlessly reduce their breathing rate to a "therapeutic zone" of less than 10 breaths per minute. The breathing exercises with RESPeRATE relax the constricted muscles surrounding the small blood vessels, allowing the blood to flow more freely and yielding a significant and lasting reduction of blood pressure within weeks.

About InterCure Ltd. and RESPeRATE

InterCure Ltd. (Tel-Aviv Stock Exchange: INCR) is disrupting the $42 billion hypertension industry with the world's first FDA-cleared, OTC blood pressure treatment device, RESPeRATE® (www.resperate.com). In a market where seven out of 10 hypertensives are NOT controlled despite the availability of more than 100 blood pressure medications, RESPeRATE provides an effective adjunctive non-drug therapy with no side effects.

RESPeRATE has gained widespread support of hypertension specialists and has secured regulatory clearance in most key international markets. Ten separate clinical studies have proven the device's efficacy and safety, and RESPeRATE is now featured in more than 20 popular and professional text books.

With more than 100,000 units sold, thousands of supportive clinicians worldwide and one of the world's most popular hypertension websites, InterCure is now introducing RESPeRATE into retail pharmacies to increase access to hypertension sufferers.

InterCure has an exciting product pipeline based on its broadly-patented "Device-Guided Breathing" technology platform. This technology enables a systematic reduction in sympathetic outflow of the autonomic nervous system, one of the key underlying causes of cardiovascular disease, insomnia and several other medical conditions.

Forward-Looking Statements

This news release may contain forward-looking statements that are based on the Company's current beliefs and assumptions and on information currently available to its management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. As a result of these risks, uncertainties and other factors, readers are cautioned not to place undue reliance on any forward-looking statements included in this press release. These forward-looking statements represent beliefs and assumptions only as of the date of this news release, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future